{"prompt": "['86', 'MC1488 WEE1', 'MCCC', 'Dasatinib', 'Nisoldipine', 'Dihydroergotamine', 'Paclitaxel', 'Disopyramide', 'Pazopanib', 'Dronedarone', 'Perospirone', 'Docetaxol', 'Pimozide', 'Dofetilide', 'Propafenone', 'Doxorubicin', 'Propofol', 'Ebastine', 'Quetiapine', 'Eletriptan', 'Quinidine', 'CYP2C19 Sensitive Substrates or Substrates with a Narrow Therapeutic', 'Range', 'Diazepam', 'Gliclazide', 'Lansoprazole', '(R)-Lansoprazole', '(S)-Lansoprazole', '(S)-Mephenytoin', '(R)-Mephobarbital', 'Omeprazole', '(R)-Omeprazole', 'Pantoprazole', '(+)-Pantoprazole', 'Rabeprazole', 'Tilidine']['87', 'MC1488 WEE1', 'MCCC', 'CYP1A2 Sensitive Substrates or Substrates with a Narrow Therapeutic', 'Range', 'Alosetron', 'Tacrine', 'Caffeine', 'Theophylline', 'Duloxetine', 'Tizanidine', 'Melatonin', 'Ramelteon', 'P-gp Substrates', '^Colchicine', '*Digoxin', 'Fexofenadine', 'Indinavir', 'Paclitaxel', 'Toptecan', 'Vincristine', '*If a patient requires initiation of digoxin during the study, or is already receiving treatment', 'with digoxin, monitoring of digoxin levels is recommended according to local practice (as', 'the levels of digoxin may increase). Monitoring of digoxin levels is also recommended', 'when the patient has completed dosing with study treatment (as the levels of digoxin may', 'then decrease).', '^Colchicine may be given during study, with expected less clinical efficacy and patients', 'should be carefully monitored clinically.', 'P-gp Inhibitors (Strong)', 'Cyclosporine', 'Elacridar', 'Erythromycin', 'Itraconazole', 'Ketocoanzole', 'LY335979Quinidine', 'Ritonavir', 'Valspodar', 'Verapamil', 'BCRP Substrates', 'Daunorubicin', 'Sulfasalazine', 'Doxorubicin', 'Topotecan', 'Rosuvastatin']['MC1488 WEE1', '88', 'MCCC']\n\n###\n\n", "completion": "END"}